Moens A, van der Woude CJ, Julsgaard M, et al. - In this retrospective multicentre case-control observational study, researchers evaluated pregnancy and child outcomes of vedolizumab-exposed pregnancies (VDZE) pregnancies and compared these outcomes to anti-TNF exposed (TNFE) or both immunomodulatory and biologic unexposed (CON IBD) pregnancies. For this investigation, VDZE group involved 79 pregnancies in 73 IBD women. In 164 IBD women and 184 pregnancies (163 live births) in 155 IBD women, respectively, the TNFE and CON IBD group included 186 pregnancies (162 live births). There was no substantial difference between groups in the rates of miscarriage. Median gestational age and birthweight were comparable between groups in live-born infants. No malignancies were recorded and infants' infection risk did not significantly differ between groups during the first year of life. No new safety signals are found in VDZE pregnancies, although the verification requires larger, prospective studies.